Myeloproliferative syndromes, including essential thrombocythemia, can result from mutations in the JAK2, CALR, and MPL genes, each acting as drivers of the fusion protein BCR-ABL1 to increase cell (platelet as well as leukocyte) production.34 This evidence concerns the gene ABL1 and essential thrombocythemia.